#China #Shanghai #Alibaba #Tencent #StairMed

StairMed's Landmark Financing Round

In a transformative move for the realm of brain-machine interfaces, Shanghai StairMed Technology Co., Ltd. has successfully closed a substantial RMB 500 million financing round. Led by industry giant Alibaba and supported by prominent investors like Tencent and Fountainbridge Capital, this funding marks a pivotal moment for the company. Notably, it comes as StairMed’s total funding in the past year surpasses RMB 1.1 billion, underscoring the confidence leading firms have in its innovative medical technology.

A Unique Collaboration

The recent financing is particularly noteworthy as it illustrates a rare collaboration between Alibaba and Tencent, two of China's largest technology firms venturing into the brain-machine interface (BMI) sector. This partnership highlights not only the escalating interest in BMI technologies but also a strategic alignment that may redefine the landscape of healthcare and information technology.

Accelerating Clinical Innovations

With the infusion of capital, StairMed is set to expedite the development of its technology platform and clinical initiatives. In the previous year, the company achieved significant milestones, including three successful clinical implants of its BMI system, which was registered with Chinese authorities. Their proprietary surgical robot enabled the implantation of a cutting-edge 256-channel wireless high-throughput invasive BMI system, marking a historic achievement as the first of its kind in China.

Continuing to push boundaries, StairMed is gearing up for large-scale, multi-center clinical trials slated to begin mid-2026. Its ambitious plan involves enrolling approximately 40 patients within the year to test and validate its BMI technologies. By the end of 2026, StairMed anticipates significantly increasing its number of implanted patients, positioning itself as a leader in the invasive BMI domain, thus solidifying its crucial role in the global medical technology landscape.

Expanding Neuromodulation Initiatives

Beyond the brain-control features of its current offerings, StairMed is broadening its horizons by developing a neuromodulation system utilizing ultra-flexible microelectrode technology. This system promises to deliver low-damage deep brain stimulation (DBS) options, matching international benchmarks for innovative therapeutic interventions. Following its implementation in clinical research, this technology will pave the way for future trials aimed at treating conditions like Parkinson's disease and epilepsy.

Strategic Vision for the Future

The founder of StairMed, Li Xue, expressed gratitude towards existing stakeholders for their unwavering support while also welcoming Alibaba and SDIC Unity Capital to their capital injection. He emphasized the significance of involving major technology players in BMI development, highlighting that more than merely a medical technology initiative, this collaboration serves as a convergence point for life sciences and cutting-edge IT solutions. With advancements in computing and artificial intelligence playing a crucial role in evolving BMIs, this strategic alignment might be paramount to developing next-generation interaction systems.

About StairMed

Founded in 2021, StairMed has positioned itself at the forefront of minimally invasive, implantable brain-machine interfaces. Equipped with innovative technologies for electrodes and surgical robotics, StairMed's mission to merge brain and machine intelligence showcases its commitment to revolutionizing treatment methods for movement disorders and neurological diseases. With robust backing from tech giants and a clear vision for future growth, StairMed is poised to make significant contributions to the BMI landscape in China and beyond.